1.18
-0.01(-0.84%)
Currency In USD
| Previous Close | 1.19 |
| Open | 1.2 |
| Day High | 1.21 |
| Day Low | 1.16 |
| 52-Week High | 2.68 |
| 52-Week Low | 1 |
| Volume | 820,577 |
| Average Volume | 1.72M |
| Market Cap | 186.37M |
| PE | -13.11 |
| EPS | -0.09 |
| Moving Average 50 Days | 1.33 |
| Moving Average 200 Days | 1.53 |
| Change | -0.01 |
If you invested $1000 in Heron Therapeutics, Inc. (HRTX) 10 years ago, it would be worth $60.76 as of February 21, 2026 at a share price of $1.18. Whereas If you bought $1000 worth of Heron Therapeutics, Inc. (HRTX) shares 5 years ago, it would be worth $64.13 as of February 21, 2026 at a share price of $1.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Heron Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, February 26, 2026
GlobeNewswire Inc.
Feb 17, 2026 1:30 PM GMT
CARY, N.C., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Thursday, F
Heron Therapeutics Announces Preliminary, Unaudited Q4 and Full-Year 2025 Net Revenue; ZYNRELEF® Largest Contributor to Q4 Growth
GlobeNewswire Inc.
Jan 09, 2026 2:29 PM GMT
CARY, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (Nasdaq: HRTX) (“Heron” or the “Company”), a commercial-stage biotechnology company, today announced preliminary, unaudited fourth quarter and full-year 2025 net revenue. “We ar
Heron Therapeutics Announces Inclusion of APONVIE® (aprepitant) Injectable Emulsion in the Newly Released Fifth Consensus Guidelines for the Management of Postoperative Nausea and Vomiting (PONV)
GlobeNewswire Inc.
Dec 04, 2025 1:15 PM GMT
APONVIE, an aprepitant product, highlighted as the only FDA-approved IV formulation Neurokinin-1 (“NK-1”) antagonist indicated for the prevention of PONV in adults, with a long half-life and quicker onset than oral aprepitantAprepitant alone, or adde